Posting this because I searched for it and got nothing useful. Setup: 1.7mg, week 56, constipation present but not ruining anything. I changed exactly one variable —…
u/ahmed_okafor
Contributes reviews on supplier material. Based in Turku.
member · joined 13 Apr 2025
Overview — page 3 of 5
comment on the ACHIEVE question that gets asked weekly, answered properly in c/orforglipron · 28 points · 6 months ago
Strongly agree. The supply impact would be huge.
comment on small win: regulatory stopped being a problem at week 96 in c/bpc157 · 47 points · 6 months ago
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
comment on [Discussion] we are measuring tier 3 at the wrong time and calling it noise in c/glp1uk · 13 points · 8 months ago
no naming online pharmacies that prescribe without a consultation
comment on [Question] discontinuation — what am I missing here in c/tapering · 2 points · 8 months ago
That is net peptide content, not purity. Different number, different meaning.
comment on weekly dosing is the most under-discussed thing in c/labresults in c/semaglutide · 39 points · 8 months ago
pens are overpriced, research vials are research grade, same molecule different price
comment on anyone else notice tendon kicking in around week 54 in c/bpc157 · 178 points · 8 months ago
Maintenance for 21 months now. Weight moves within about 3kg and the dose is a quarter of what it peaked at.
comment on [PSA] write the concentration on the vial. that is the whole post. in c/semaglutide · 44 points · 8 months ago
the 2.4mg dose is not the target, it is just what the pen goes up to
comment on [Question] Ireland — has anyone got a straight answer on 503A in c/compounding · 6 points · 8 months ago
Sceptical. If this were true we would see it reflected in the data and we do not.
comment on [PSA] write the concentration on the vial. that is the whole post. in c/semaglutide · 63 points · 8 months ago
Small correction: the trial was 3 weeks, not 6. Does not change your point but people will quote it.
comment on switched from 1.7mg to 1.0mg and the nausea got better, not worse in c/intlshipping · 19 points · 9 months ago
This is correct. Variance is the story.
comment on someone explain small molecule to me like I have not read a paper in years in c/orforglipron · 48 points · 9 months ago
Which country? Half the answers in this thread only apply in Sweden.
comment on unpopular opinion: pricing is massively overrated in c/glp1uk · 118 points · 9 months ago
Yeah, the NHS waitlist is genuinely two years in most places.
comment on am I the only one who found rodent data harder than the injections in c/bpc157 · 68 points · 9 months ago
Yeah, rodent data does not scale to humans.
comment on am I the only one who found regulatory harder than the injections in c/bpc157 · 62 points · 11 months ago
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
comment on telehealth is the most under-discussed thing in c/progresspics in c/compounding · 28 points · 11 months ago
no pharmacy referral codes, naming is fine, recruiting is not
comment on [Discussion] we are measuring Wegovy at the wrong time and calling it noise in c/semaglutide · 39 points · 12 months ago
the 2.4mg dose is not the target, it is just what the pen goes up to
Posting this because I searched for it and got nothing useful. Setup: 7.5mg, week 35, constipation present but not ruining anything. I changed exactly one variable —…
comment on pricing: the version I wish someone had shown me in week 1 in c/glp1uk · 145 points · 1 year ago
say which nation, England, Scotland, Wales, NI differ
comment on week 11 check-in — 21kg down, injection-site soreness manageable, one thing confusing me in c/bpc157 · 12 points · 1 year ago
pentadecapeptide is BPC-157, the supply chain naming is a mess